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During the current opioid crisis, hospitalizations for the treatment of intravenous 
drug use-related infective endocarditis have increased.  Despite this, opioid use disorder 
is inadequately treated resulting in continued drug use, higher surgical intervention, 
recurrence and mortality rates relative to non-drug use-related endocarditis. 
 Buprenorphine* is a safe and effective medication-assisted addiction treatment in 
outpatient settings; however, buprenorphine remains underutilized, particularly among 
patients hospitalized for infective endocarditis. Emergency department-initiated 
buprenorphine combined with referral to ongoing treatment is associated with improved 
rates of addiction treatment engagement. Therefore, our objective is to investigate 
whether hospital-initiated buprenorphine combined with referral in patients with opioid 
use disorder admitted for infective endocarditis is more effective than referral alone for 
treatment engagement 30 days post-hospital discharge.  These results may optimize our 
standard of care for patients with intravenous drug use-associated infective endocarditis 
to enhance enrollment in treatment for opioid use disorder. 
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Chapter 1 Introduction:   
1.1 Background 
Intravenous drug use (IVDU) rates in the United States have doubled between 2006 
and 2013.20  People who inject drugs (PWID) are at increased risk for serious infections 
such as infective endocarditis (IE) through the direct injection of bacteria or the spread of 
injection site abscesses into the bloodstream.2,6,14,16,20,21  Among various institutions, the 
increasing prevalence of IVDU is accompanied by more than a sevenfold increase in IE 
diagnoses and up to a fivefold increase in surgical tricuspid valve interventions.6,20  
Nationally, up to 20% of PWID are reported to have had IE.21  Moreover, data from the 
National Inpatient Sample, which represents 20% of U.S. non-federal, community 
hospitals, indicates that the incidence of hospitalizations between 2009 and 2013 for IE in 
persons with substance use disorder increased from 12.3% to 23.2%, p<0.0001.2   
Recurrence and readmission rates of IE are as high as 50% and are directly 
proportional to the 50% prevalence of active drug use among patients hospitalized with 
IVDU-related conditions.10,14,21  These recurrences come with high costs.  IE has a 5-year 
mortality rate of 50% and up to 26% inpatient mortality rate.21  The cost of 
hospitalization for IE increased between 2009 and 2013 from $49,669 to $57,389, 
p<0.0001 with length of hospital stays averaging from 17 days to 31 days across the 
literature.2,6,7,10  Treatment strategies for these patients are typically focused on infection 
management but not the causative underlying addiction.5,14 
Medication-assisted treatment (MAT) for opioid use disorder (OUD), which is 
commonly seen in association with IVDU improves morbidity and mortality.5,9  
Buprenorphine has proven safety and efficacy for treating withdrawal symptoms, 
 2 
decreasing craving for opioids and improving substance use-related outcomes including 
treatment engagement, substance use, and substance use-related complications in both 
inpatient and outpatient settings.4,9,11,12,16,17  Emergency department (ED) initiated 
buprenorphine treatment for OUD combiuned with referral to ongoing addiction 
treatment is associated with enhanced treatment engagement following discharge from 
the ED.3,4  ED-initiated buprenorphine coupled with referral is also proven to be more 
cost-effective for the healthcare system than referral strategies alone ($97 versus $283-
322, p<0.001).1  In spite of this, substance abuse treatment is woefully underutilized.14,15 
Looking beyond ED visits, hospitalizations may also provide a golden opportunity for 
interventions to be introduced.5,8,10,12,13,15-17,19  15% of all hospitalized patients have a 
substance use disorder and intervention approaches are inadequately focused solely on 
referral to addiction treatment after discharge.18,19  In one retrospective case study, 62% 
of patients with OUD who were admitted for intravenous drug use-related infective 
endocarditis (IVDU-related IE) accepted MAT, and half of these accepted hospital-
initiated buprenorphine.16  In another retrospective case study, 46.8% of hospitalized 
patients identified with opioid dependence whom accepted buprenorphine induction, 
initiated addiction treatment within 2 months of discharge.17  
 
1.2 Statement of the Problem 
The incidence of IVDU-related IE is increasing in the context of a national opioid-use 
epidemic.  Addiction treatment during hospitalizations for IVDU-related IE is often 
overlooked, and if it occurs at all, is largely focused on post-discharge referral to 
subsequent addiction treatment rather than a hospital-initiated addiction treatment 
 3 
intervention.  As a result, transition and adherence to addiction treatment after IVDU-
related IE hospitalization is low, while IVDU-related IE hospital readmissions and 
associated morbidity, mortality, and recurrence rates are on the rise, despite the 
availability of effective medication-assisted treatment options like buprenorphine.  To 
date, research on hospital-initiated buprenorphine for the treatment of opioid use disorder 
is severely limited.  The data that does exist suggests the utility of hospital-initiated 
buprenorphine but has mostly come from small studies that were insufficiently powered 
to demonstrate effectiveness and has not focused on patients with IE.  This warrants 
further research to investigate whether incorporation of buprenorphine in the treatment of 
patients hospitalized for IVDU-related IE facilitates addiction treatment engagement after 
discharge, in support of IVDU-related IE recurrence prevention.  
 
1.3 Goals and Objectives 
We propose a multicenter, randomized clinical trial to optimize addiction 
treatment in patients with OUD who are hospitalized for IVDU-related IE.  This study 
aims to compare the efficacy of hospital-initiated buprenorphine alongside an Addiction 
Medicine referral for ongoing buprenorphine treatment versus referral only, for opioid 
use disorder addiction treatment engagement after hospital discharge.   
 
1.4 Hypothesis 
Among patients hospitalized for IVDU-related IE, we predict that compared to 
referral-only patients there will be a statistically significant higher proportion of patients 
engaged in addiction treatment among hospital-initiated buprenorphine patients, 
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Abbreviation: IVDU-related IE = intravenous drug use-related infective endocarditis 
*Buprenorphine = refers to combination drug buprenorphine/naloxone. 
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Chapter 2 Review of the Literature: 
2.1 Introduction  
The databases used for this literature review include PubMed, Cochrane Library, 
ScienceDirect, Web of Science, EMBASE Ovid, and Scopus.  All publications were 
searched using the keywords and phrases endocarditides, infective endocarditides, 
infective endocarditis, drug abuse, drug addiction, drug dependence, drug use disorder, 
substance abuse, substance addiction, substance dependence, substance use disorder, 
intravenous drug abuse, intravenous substance abuse, parenteral drug abuse, medication 
assisted treatment of opioid, opiate medication assisted treatment, opiate replacement 
therapy, opiate substitution treatment, opioid medication assisted treatment, opioid 
replacement therapy, opioid substitution therapy, buprenorphine, RX6029M, and 6029M.  
The resulting set of references were examined to include relevant reports, reviews, meta-
analyses, and clinical trials. 
 
2.2 Drug Use Disorder Epidemiology 
 Opioid use disorder is a brain disorder provoked by recurrent opioid use that 
causes gamma-aminobutyric acid (GABA) inhibition thru mu receptor interaction, 
followed by increased dopamine release.1,26  The ultimate result is neuronal remodeling at 
the nucleus accumbens, amygdala, and prefrontal cortex within the mesocorticolimbic 
dopamine systems, or the “reward systems,” of the brain.1  Long-term opioid use also 
desensitizes and increases the number of opioid receptors such that tolerance levels rise.1  
Discontinuation of opioids precipitates a “noradrenergic storm” we refer to as 
withdrawal.1  Symptoms of withdrawal include: yawning, lacrimation, rhinorrhea, 
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nausea, emesis, diarrhea, hypertension, chills, piloerection, myalgias, abdominal pain, 
tremor, anxiety, agitation, delirium, and seizures.1 
 According to the United Nations Office on Drugs and Crime (UNODC) and the 
World Health Organization (WHO), there are 15.6 million people with opioid use 
disorder worldwide, 71% of whom use heroin.1  The economic burden of opioid use 
disorder ranges from 0.2 to 2% of a country’s gross domestic product secondary to 
healthcare costs, social welfare services, criminal justice demands, and unemployment.1 
 Throughout the United States, the rate of heroin use doubled between 2006 and 
2013.25  Approximately 3% of the American population (n=9.8 million) has injected 
drugs.6,13  In Virginia, a retrospective chart review identified an 89% increase in 
emergency room visits for heroin overdose in 2015 compared to 2014.10,20  Another 
retrospective chart review in Kentucky identified 335 hospitalizations associated with 
intravenous drug use (IVDU) between 2012 and 2015; 108 were included in the study.13  
95.4% of these hospitalizations had explicit documentation of illicit opioid use during 
admission, however, only 57.4% were formally diagnosed with a substance use disorder, 
a mere 2.8% received medication-assisted addiction treatment, and a lamentable 16.7% 
received an addiction treatment referral at discharge.13   
These studies offer small representations of the United States that complement 
national analyses reporting an opioid epidemic.  Overall, the data suggest a recent and 





2.3 Intravenous Drug Use-Related Infective Endocarditis   
Persons who inject drugs are at an increased risk for death and IVDU-related 
infections.5,10,11,19,27  Intravenous drug use-related infective endocarditis (IVDU-related 
IE) typically presents as right-sided heart disease involving endothelial damage to the 
tricuspid valve.10,11,25,27  The tricuspid valve is the first heart valve to interact with the 
returning venous circulation. 10,11,25,27  In patients with history of IVDU, this blood often 
carries microorganisms and particulate matter introduced during injection or from the 
hematogenous spread of soft tissue infections caused by injection.10,11,25,27  Up to 20% of 
persons who inject drugs have had infective endocarditis (IE), at an incidence rate 100 
times greater than in the general population.3,10,27   
In 2013 at the Hospital of the University of Pennsylvania (HUP), IVDU-related 
IE hospitalizations accounted for 12% of total hospitalizations.25  In a retrospective 
descriptive review of all surgical tricuspid IE cases at HUP (n=783), surgical IVDU-
related IE cases exhibited a 5-fold increase between 2011 and 2017 from 7 cases to 32 
cases per year, respectively.25  Additionally, a history of illicit drug use in patients with 
IE rose from 14.3% to 81.8% during this same time period.25  Of note, the median patient 
age decreased from 52.85 years to 39.2 years and overall 30-day post-operative mortality 
in this population was 11.11%.25  These results are in agreement with the current opioid 
epidemic within the U.S., as well as the increased risk of IE associated with IVDU. 
The National Inpatient Sample (NIS) database includes approximately 20% of all 
non-federal, community hospital discharges in the U.S.5,27  A cross-sectional study used 
NIS to identify IVDU-related IE discharges from 2000 to 2013.27  Wurcel et al. found 
that the proportion of IVDU-associated IE discharges among total IE hospitalizations 
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increased significantly from 7% to 12.1%, and a parallel significant increase in IVDU-
related IE among patients 15 to 34 years old from 27.7% to 42%, p<0.001.27  A reciprocal 
significant decrease in IVDU-related IE rates occurred in patients 35 to 54 years old from 
67.2% to 39.9%, p<0.001.27  Of note, rate changes were most significant between 2008 
and 2013, which corresponds with the significant increases in heroin use of the period. 
Another cross-sectional study utilized NIS to analyze IVDU-related IE hospital 
discharges between 2009 and 2013.5  During this period, overall IE hospitalization rates 
remained stable, but the prevalence of substance use disorder significantly increased from 
12.3% to 23.2%, p<0.0001.5  The percentage of IE in patients 65 years significantly 
decreased from 40.6% to 32.9%, p<0.0001, while the percentage of IE in patients 39 
years reflected a significant rise.5  More specifically, in patients <18 years old IVDU-IE 
rates rose from 1.1% to 2.1%, p=0.0261 and in patients 18 to 39 years old IVDU-IE rates 
increased from 17% to 24.2%, p<0.0001.5   
Both studies using NIS presumed a diagnosis of IVDU-related IE through the 
inclusion of discharges with ICD-9 codes for IE and substance use disorder, and 
concurrent exclusion of discharge codes for other IE risk factors like history of rheumatic 
disease.  These data strongly suggest a correlation between substance use disorder and IE 
in the hospitalizations, but due to the retrospective design of the studies a direct 
association could not be established.5 
At Wake Forest Baptist Medical Center, a retrospective chart review compared 
IVDU-related IE hospitalizations to non-IVDU-related IE hospitalizations between 2009 
and 2014.11  During this time the proportion of IVDU-IE increased from 14% to 56%.11  
The median age for patients with IVDU-related IE was 32.6 years, as opposed to 54.4 
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years in patients with non-IVDU-related IE, p<0.0001.11  Similarly, a retrospective cohort 
study in Virginia identified a 7.54-fold increase in IVDU-related IE from 2000 to 2016 at 
the University of Virginia Medical Center.10  As with previous studies, this study also 
indicated that IVDU-related IE is more likely in younger adults with a mean age of 35 
years in contrast to a mean age of 61 years among non-IVDU-related IE, p<0.001.10  Of 
note, the average cost of admission was almost double for IVDU-related IE than for non-
IVDU-related IE at $47,899 versus $26,460 (p=0.001), respectively.10   
The reproducibility of results in the literature strongly supports a correlation 
between IVDU and IE, the increasing rates of IVDU-related IE in the United States, and 
the higher financial burden that IVDU-related IE represents relative to non-IVDU-related 
IE.  Causation could not be determined in these studies secondary to their retrospective 
design.  The retrospective designs also pose a risk for selection bias that threatens 
underrepresentation of IVDU and associated IE, secondary to improper ICD-9 coding in 
the hospitalizations that were screened.  Finally, with the exception of the NIS studies, 
these were single-center studies that offered limited generalizability.  
 
2.4 Medication-Assisted Addiction Treatment: Buprenorphine/Naloxone 
WHO defines the goals of medication-assisted treatment (MAT) of opioid use 
disorder as: “reduction or cessation of illicit opioid use, injection, and associated risk of 
bloodborne virus transmission; reduction of overdose risk and criminal activity; and 
improvement of psychological and physical health.”1  Available options for MAT include 
naltrexone, buprenorphine, and methadone.6 
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In a study comparing the efficacy of extended-release naltrexone injections and 
sublingual buprenorphine therapy, 94% of patients successfully inducted to 
buprenorphine versus 72% in naltrexone patients (HR 1.36, 95% CI 1.1 – 1.68, 
p<0.0001).15  Relapse rates were significantly greater in the naltrexone group than the 
buprenorphine group at 65% and 57% (p=0.036), respectively.15  Buprenorphine patients 
also provided a significantly higher average of opioid-negative urine samples 
(buprenorphine: 10 negative samples vs. naltrexone: 4 negative samples, p<0.0001).15  
These results concur with WHO recommendations for MAT with an opioid agonist.1    
Opioid-agonist maintenance treatment, with methadone or buprenorphine, 
alongside psychosocial assistance is the most effective treatment option for opioid 
dependence when compared to detoxification or no treatment.1,6,8,9,12,21,24  Buprenorphine 
significantly decreases drug use and increases addiction treatment engagement.1  
Buprenorphine is also associated with fewer side effects and drug-drug interactions than 
methadone.1,6   
Of note, buprenorphine use can be diverted for injection to produce strong effects.  
Buprenorphine/naloxone combination products at a 4:1 ratio were developed in an effort 
to minimize diversion.1  Sublingually, buprenorphine affinity supersedes naloxone 
affinity.1  However, with injection of the combination product naloxone induces 
withdrawal in opioid-dependent individuals.1,6 
Buprenorphine dosing is patient-specific based on their opioid use and tolerance 
level.1  It should be initiated at a low dose and quickly increased over days, typically to a 
dose between 8-24 mg.1  Fixed buprenorphine doses > 6 mg are as equally effective as 
fixed methadone doses > 40 mg in addiction treatment retention and illicit opioid use 
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suppression.17  Buprenorphine doses of 16 mg are superior to placebo for addiction 
treatment retention (RR 1.52, 95% CI 1.23 to 1.88) and greater opioid-negative urinalyses 
(SMD –0.65, 95% CI –0.86 to –0.44).1  Buprenorphine doses > 16 mg are also superior to 
placebo for addiction treatment retention (RR 1.82, 95% CI 1.15 to 2.9) and greater 
opioid-negative urinalyses (SMD –1.17, 95% CI –1.85 to –0.49).17   
In a retrospective study at the University of Virginia Medical Center, of 76 
patients with IVDU-related IE only 13% received medication-assisted addiction 
treatment (MAT).10  63% had a prescribed opioid documented on their discharge 
medication list, and only 53% had IVDU or a substance use disorder diagnosis 
documented on their discharge summary.10   
In another similar study out of Beth Israel Deaconess Medical Center in Boston, 
of 102 patients hospitalized for IVDU-related IE, addiction was only mentioned in 55.9% 
of discharge plans, only 7.8% had MAT plans, and none were prescribed naloxone for 
harm reduction.19  Of note, 13.7% had recurrent IVDU-related IE and 49% were “ever 
readmitted,” with a 32.1% rate of readmission IVDU documentation.19   
The data from these efficacy trials strongly supports the utility of buprenorphine 
in addressing opioid use disorder.  However, the descriptive studies are reflective of the 
problem of unaddressed addiction treatment in patients with substance use disorder, 
despite its potential to improve patient outcomes, decrease hospital visits and thereby 




2.5 Hospital-Initiated Medication-Assisted Treatment 
Since 2000 IVDU-related infections have increased more than 70%, leading to 
more frequent healthcare utilization.14,16,22,24,27  Opioid-related emergency department 
visits have increased by 183% between 2004 and 2011, a quarter of who are 
admitted.2,14,16  Approximately 15% of hospitalized patients have an active substance use 
disorder.24  Healthcare providers have a unique opportunity to identify and treat 
substance use disorder.13,21,23   
 In a randomized clinical study performed at Boston Medical Center (BMC), 337 
hospitalized patients were referred for inpatient addiction consultation services.24  78% of 
the patients were diagnosed with opioid use disorder.24  110 patients received opioid-
agonist treatment with methadone or buprenorphine.  67% of these patients transitioned 
to outpatient addiction treatment after discharge, 50% remained engaged in treatment at 
30 days, 35% remained engaged at 90 days, and 25% at 180 days.24  Of the 
buprenorphine patients, 49% transitioned to outpatient addiction treatment after 
discharge, 39% remained engaged in treatment at 30 days, 27% remained engaged at 90 
days, and 18% at 180 days.24   
The addiction consultation services at BMC are a model for optimized addiction 
treatment in an inpatient setting.  This serves as a limitation for the generalizability of this 
study, because it is a highly specialized team comprised of an attending physician and 
fellows specializing in Addiction Medicine, Internal Medicine and Family Medicine 
residents, a social worker, and a psychiatrist with case management collaboration.24  This 
type of coordinated care for inpatient substance use disorder identification and 
intervention is not yet ubiquitous throughout the healthcare system.  This specialty 
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service, along with the single-center setting for the study, negatively affect the 
generalizability of its results.  Moreover, no control group was included in this study for 
comparison. 
 A randomized clinical trial at Butler Hospital screened patients hospitalized for 
any reason for opioid dependence.16  Identified patients were offered the choice to start 
methadone treatment or participate in the study comparing buprenorphine and 
detoxification.16  Of the 72 patients that initiated hospital-buprenorphine, 72.2% engaged 
in outpatient addiction treatment within 6 months of discharge compared to the 11.9% 
randomized to detoxification, p<0.001.16  Addiction treatment engagement at 6 months 
after discharge was 16.7% in the buprenorphine group in contrast to 3% in the 
detoxification group, p<0.007.16  These data reinforce the superiority of opioid agonist 
MAT in addiction treatment and the opportunity hospitalizations provide for MAT 
initiation for effective transition to outpatient addiction treatment.  This study is limited 
by its single-center setting that compromises generalizability and high attrition rates.  It is 
also threatened by information bias secondary to research interviewers being privy to 
treatment group assignments at follow-up appointments.   
 A retrospective study at a Partners hospital in Boston, MA identified 47 cases of 
patients diagnosed and treated for DSM-IV opioid dependence between 2013 and 2014.22  
Addiction treatment consisted of Clinical Opioid Withdrawal Scale-driven buprenorphine 
induction and maintenance, followed by referral to addiction treatment services at 
discharge.22  46.8% of these patients engaged in outpatient treatment.22  This study is 
limited by a small sample size and a retrospective design that only suggests a correlation 
between hospital-initiated and engagement in outpatient addiction treatment.22  However, 
 15 
these findings are consistent with the results from the aforementioned prospective 
studies.16,22,24 
 D’Onofrio et al. investigated emergency department initiated-buprenorphine at 
Yale New Haven Hospital.8  Between 2009 and 2013, all patients 18 years or older were 
screened for opioid use disorder.8  329 patients were identified with DSM-IV opioid use 
disorder diagnoses and were randomized to receive either (1) referral to outpatient 
addiction treatment, (2) brief intervention via motivational interviewing alongside referral 
to outpatient addiction treatment, or (3) brief intervention alongside buprenorphine and 
referral to outpatient addiction treatment.8  Engagement in addiction treatment at 30 days 
following randomization was significantly higher in the buprenorphine group (78%, 95% 
CI, 70% – 85%) compared to the referral group (37%, 95% CI, 36% – 54%) or brief 
intervention group (45%, 95% CI, 36% – 54%), p<0.001.8  The buprenorphine group also 
reported a significant reduction in weekly illicit opioid use from an average of 5.4 days to 
0.9 days, p<0.001.8  Long term assessments of the D’Onofrio study were performed to 
find that 74% in the buprenorphine group were engaged in addiction treatment at 2 
months compared to 53% in referral group or 47% in the brief intervention group, 
p<0.001.7  At the 2 month follow-up, self-reported illicit opioid use in the past 7 days was 
also significantly lower in the buprenorphine group with an average of 1.1 days in 
contrast to 1.8 days in the referral group and 2 days in the brief intervention group, 
p=0.040.7  Secondary analyses comparing costs between the interventions indicate that 
ED-initiated buprenorphine is most cost-effective, when considering only healthcare 
system costs.4  These results support the general superiority of hospital-initiated 
buprenorphine for engagement to outpatient addiction treatment compared to referral 
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with or without motivational interviewing.  This study’s outcome analyses were limited 
by insufficient power and attrition rate.  Information bias in self-reports for opioid use 
poses a threat to validity.  And, the context of a single-center affects generalizability. 
Overall, these studies are suggestive of the feasibility in initiating emergency room or 
inpatient medication-assisted addiction treatment.16,23,24  The results support the 
effectiveness of hospital-initiated MAT, and buprenorphine specifically, for engaging 
patients in addiction treatment after discharge in a financially prudent manner.24 
 
2.6 Conclusion  
At present, the role of hospitalists is not well-defined for the treatment of opioid 
use disorder.6,23  Current data validates opioid use disorder as a condition that is most 
effectively treated with opioid-agonist addiction treatment and psychosocial support.  The 
prevalence of opioid use disorder among patients presenting to the emergency room and 
whom are hospitalized is well-established, particularly in those presenting with infections 
attributable to IVDU.  Unfortunately, these studies have been limited by insufficient 
power, lack of generalizability, and information bias.  Our study addresses some of these 
limitations through a prospective, randomized clinical design to establish causation in a 
multicenter context to support generalizability.  Our study will include a referral-only 
control group for comparison, and it will blind its research associates involved in follow-
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Chapter 3 Study Methods:  
3.1 Study Design 
This 24-month multicenter, randomized clinical trial will recruit patients (18 years 
or older) with opioid use disorder hospitalized for intravenous drug use-associated 
infective endocarditis (IVDU-IE).  The study will be conducted by Yale New Haven 
Hospital and Partners HealthCare, to include 17 hospitals throughout the Northeast 
United States. Physician and other healthcare professional members of the Addiction 
Medicine subspecialty will be invited to participate in this collaborative study.  Protocol 
for this study will be submitted for review by the Institutional Review Board (IRB) at 
each participating center. 
3.2 Study Population and Sampling 
We will practice convenience sampling using electronic medical records (EMR) 
to identify patients hospitalized with a diagnosis of infective endocarditis.  Each patient 
will be clinically screened using the ASSIST-Drug tool for IVDU and DSM-V diagnosis 
of opioid use disorder, and diagnostically screened via urine toxicology for presence of 
opioids (Table 1).8,9  We expect to enroll 196 adults, with 98 adults in the buprenorphine 
group and referral-only group, respectively.  
 
Table 1.  ASSIST-Drug Screening Tool Validity Against the MINI Screening Tool 
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3.2.1 Inclusion Criteria 
Patients must meet ALL of the following criteria to enroll in the study: 
1. 18 years or older at the time of screening. 
2. DSM-V diagnosis of opioid use disorder. 
3. Urine sample positive for non-prescribed opioids on hospital admission. 
4. Ability and willingness to provide written consent. 
3.2.2 Exclusion Criteria 
Patients who meet ANY of the following criteria will be excluded from the study:  
1. Present condition compromises safety or compliance. Examples include: pre-
operative, intensive care unit admission, dementia, suicidal, or homicidal. 
2. Currently receiving formal addiction treatment.  
3. Contraindication and/or allergy to buprenorphine. 
4. Requirement of opioids for chronic pain management. 
5. Currently enrolled in another study.  
6. Pregnant and/or breastfeeding. 
7. Patients in police custody. 
3.3 Subject Protection and Confidentiality 
This study will be reviewed by the Human Investigation Committee for required 
approval prior to performing.  In compliance with Institutional Review Board (IRB) 
requirements (Policy 200) and current HIPAA regulations, all prospective study 
participants will be informed of the study’s purpose and counselled on the risks and 
benefits of buprenorphine in a manner and language that is understandable.  Patients will 
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receive an invitation to participate without coercion, understanding that their participation 
is voluntary and may be withdrawn at any time.  Written informed consent will be 
obtained from all study participants prior to all procedures. Interpreters and translated 
research document will be used, as necessary.   
3.4 Recruitment 
Study participants will be prospectively enrolled during the first 18 months of the 
study.  Patients initially admitted to preoperative care or intensive care units can enroll 
after surgery and transfer to a medical floor.  Post-operative narcotic analgesia course 
must be completed prior to enrollment.   
3.5 Interventions 
 After obtaining written informed consent, study participants will be asked to 
complete baseline assessments, and then will be randomly assigned at a 1:1 ratio to 1 of 
the 2 groups using a computerized stratified randomization procedure to ensure equal 
distribution of post-operative patients and those solely medically-managed.3,4,7  
Randomization will be under the control of an investigator not involved with enrollment 
or data collection.3,4,7   
3.5.1 Buprenorphine Group 
Patients in the buprenorphine group will receive hospital-initiated sublingual 
buprenorphine alongside referral to Addiction Medicine for ongoing buprenorphine 
treatment of opioid use disorder.   
We will provide pamphlets that include provider names, locations, and telephone 
numbers for addiction treatment centers that are covered by each patient’s insurance.  The 
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addiction treatment centers we refer to will offer services that include various treatment 
options such as inpatient and outpatient settings, opioid-agonist treatment with 
methadone or buprenorphine, detoxification and naltrexone treatment, as well as 
psychosocial support services. 
We will initiate buprenorphine when a patient exhibits moderate-to-severe opioid 
withdrawal using the Clinical Opiate Withdrawal Scale (COWS) (Table 2).1,3,10,12  We 
will administer buprenorphine 8 mg on day 1, buprenorphine 12 mg on day 2, and 
buprenorphine 16 mg daily thereafter.1  In patients who do not exhibit withdrawal prior to 
discharge, a prescription for buprenorphine will be provided with detailed instructions for 
home induction.3,5 
 
Table 2.  Clinical Opiate Withdrawal Scale 
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3.5.2 Referral-Only Group 
Patients in the referral-only group will receive an Addiction Medicine referral and 
information for addiction treatment providers in the same manner as our patients in the 
buprenorphine group. 
3.6 Outcomes and Covariates 
3.6.1 Covariates 
 Sociodemographic data and clinical characteristics will be recorded in the 
baseline assessments.  
3.6.2 Sociodemographic Data 
Patients’ sex, race/ethnicity, age, highest level of education, employment status, 
relationship status, stable housing, health insurance status, primary care provider (PCP) 
status, and usual source of care.2,3  Race includes: White, Black, Hispanic, and other. 
Highest level of education includes: high school graduate/equivalent, some college, and 
college degree.  Health insurance status includes: private/commercial, Medicare, 
Medicaid, and none. Usual source of care includes: PCP office, clinic, and emergency 
department/none. 
3.6.3 Clinical Characteristics  
Clinical characteristics data to be collected will include patients’ primary type of 
opioid used and route of administration, nonopioid substance use in the past month, 
mental health history, occurrence of any psychiatric symptom in the past month, 
depression treatment receipt in the past month, and any lifetime treatment for addiction.2,3  
Primary type of opioid drug and route of administration includes: prescription, heroin, 
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and IV use.  Nonopioid substance use in the past month includes: alcohol to intoxication, 
benzodiazepines, cannabis, cocaine, and cigarettes.  Mental health history includes: 
lifetime psychiatric diagnoses and treatment, both inpatient and outpatient. Any lifetime 
substance use disorder diagnoses and past treatment for addiction to alcohol and/or other 
drugs. 
3.6.4 Primary Outcome 
The primary outcome is engagement in addiction treatment 30 days after 
discharge.  A patient is considered engaged in addiction treatment if they are confirmed 
to be enrolled in ongoing formal addiction treatment through direct contact with the 
programs.  
3.6.5 Secondary Outcomes 
Secondary outcomes are engagement in addiction treatment 3 months after 
discharge, and urine toxicology screening for opioids at 30 days and 3 months after 
discharge.  
3.7 Blinding of Outcome 
 Research associates collecting data after discharge will be blinded to each study 
participant’s intervention assignment and corresponding inpatient course.  
3.8 Data Collection and Statistical Considerations 
3.8.1 Data Collection 
Engagement in addiction treatment will be assessed by direct contact with the 
addiction treatment facility, clinician, or both for verification of enrollment in ongoing 
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formal addiction treatment at 30 days and 3 months after hospital discharge.  Urine 
samples will be collected by research associates and analyzed using rapid qualitative 
immunoassay.3 
3.8.2 Sample Size Calculation 
Sample size calculations were based on data from published studies investigating 
the efficacy of buprenorphine initiated in emergency department (ED) and inpatient 
settings.3,11  These reports support addiction treatment engagement 30 days post-
randomization in 78% of ED-initiated buprenorphine patients and 37% of ED-referral 
patients, with an effect size of 0.41.3  Moreover in another study, 39% of hospital-
initiated buprenorphine patients were engaged in addiction treatment 30 days post-
discharge.11  This suggests a half-fold difference in positive outcomes between these 
acute care settings.  Under this assumption, we inferred 18% of hospitalized patient 
referrals would engage in addiction treatment and an anticipated effect size of 0.21.  
We will need a sample size of 144 to detect a between-group difference of at least 
54% for the primary outcome of engagement in addiction treatment at 30 days post-
discharge, with 80% power and Type I error probability 0.05.  We also considered losses 
in follow-up from published studies to anticipate a 35% attrition rate.3,6,11  Under this 
assumption, we will require a sample size of 196 to adequately power our investigation.   
3.8.3 Analysis 
Patients’ sociodemographic data and clinical considerations will be presented 
using descriptive statistics.  Primary and secondary outcomes will be described as 
proportions.  Chi-square tests will evaluate the statistical significance of between-group 
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differences in outcomes.  If necessary, multivariate analyses will be performed using 
multiple logistic regression to control for confounding.  Intention to treat analyses will be 
employed to include every enrolled study participant.  Missing urine samples will be 
reported as opioid-positive. 2-tailed tests of significance will be performed with IBM 
SPSS software.  A p-value less than 0.05 will be considered statistically significant. 
3.9 Timeline 
 This study will be divided into 2 stages. Stage 1 will be for patient recruitment 
and data collection to be completed in 24 months (Figure 1).  Buprenorphine-initiation 
protocol and referral information delivery will start immediately after randomization.  
Recruitment will conclude 6 months prior to the end of Stage 1, to accommodate 3 
months of post-discharge data collection for each individual.  Data collection will occur 
throughout Stage 1.  Stage 2 will be for data analysis.  
 
Figure 1.  Stage 1 Timeline: Recruitment and Data Collection 
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Chapter 4  Conclusion 
4.1 Advantages and Disadvantages  
Intravenous drug-use related infective endocarditis (IVDU-IE) therapy employing 
medication-assisted addiction treatment addresses the causative factor of infection 
recurrence.  However, our current standard of care approach solely emphasizes infectious 
disease management.2,7  Overall, limited data exists for opportunistic hospital-initiated 
addiction treatment, and to our knowledge, no study has focused on hospital-initiated 
buprenorphine in patients hospitalized with IVDU-IE.  It is imperative that we provide 
evidence-based recommendations to the medical community for optimization of IVDU-
IE treatment.   
We elected a randomized clinical trial study design and intention to treat analysis 
to best address treatment comparison.  Study participants cannot be blinded to their 
intervention, however, research associates will be blinded to inpatient course to minimize 
information bias.  To further limit information bias, urinalysis will be used for screening 
of opioid use after hospital discharge.  A bedside diagnosis and pharmacologic 
management are feasible interventions.  Access to 196 patients to sufficiently power the 
study is also feasible across 17 sites in 18 months.1  Additionally, our study addresses 
generalizability issues of previous studies through its geographic expansion to multiple 
sites within the Northeast United States, and by including non-English speaking patients.   
This study has several limitations. First, IVDU-IE is a highly specific diagnosis.  
In a real-world setting, patients with active IVDU that are hospitalized for any reason 
may be eligible for hospital-initiated buprenorphine.  Second, we have chosen to exclude 
patients requiring opioid management for chronic pain due to ethical and pharmacologic 
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considerations.  Chronic opioid regimens are a risk factor for IVDU and IVDU-IE, 
however, use of a partial opioid agonist like buprenorphine in these patients would either 
precipitate withdrawal or render their pain management regimen ineffective.  Methadone 
may be a better option for medication-assisted addiction treatment in these patients.1  
Third, sociodemographic variables present potential sources of confounding.  Lack of 
engagement in addiction treatment and attrition may not be entirely contingent on 
buprenorphine efficacy but on factors such as unstable living arrangements, 
unemployment, and uninsured status.  This warrants further research and optimization of 
psychosocial interventions for this patient population. Next, 3 months for data collection 
may be considered too brief because IVDU is a chronic brain condition.  However, 
patient outcomes following effective transition to addiction treatment programs are more 
reflective of ongoing treatment strategies in said programs.  Finally, initiation of 
buprenorphine may be viewed as burdensome as it necessitates that prescribers comply 
with the Comprehensive Addiction Recovery Act (CARA) by completing 8 to 24 hours 
of federally-mandated office-based opioid addiction treatment training and certification.6  
However, outpatient buprenorphine is more accessible in contrast to stringent, federally-
regulated methadone clinics.1,3,6,8  
4.2 Clinical and Public Health Significance 
If hospital-initiated buprenorphine in IVDU-IE patients proves to be more 
effective than referral alone for engagement in addiction treatment after discharge, we 
may optimize recurrence prevention of IE.  Continued work to reconcile social barriers 
and the stigma surrounding medication-assisted addiction treatment is still required, but 
this study proposes an interdisciplinary approach with currently available options sans 
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costly, innovative therapies to reduce IVDU-related morbidity and mortality.4,5,9  
Moreover, it offers an effective addiction treatment strategy amidst a national opioid 
epidemic.  
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Appendix I Sample Consent Form 
 
WRITTEN CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR.3 (2014-1)  
FOR SUBJECTS WHO DO NOT SPEAK OR ARE UNABLE TO READ ENGLISH 
THIS DOCUMENT MUST BE WRITTEN IN A LANGUAGE UNDERSTANDABLE 
TO THE SUBJECT 
 
YALE-NEW HAVEN HOSPITAL 
YALE-NEW HAVEN HOSPITAL: SAINT RAPHAEL CAMPUS 
YALE-NEW HAVEN HOSPITAL: BRIDGEPORT HOSPITAL 
YALE-NEW HAVEN HOSPITAL: LAWRENCE + MEMORIAL HOSPITAL 
YALE-NEW HAVEN HOSPITAL: WESTERLY HOSPITAL 
YALE-NEW HAVEN HOSPITAL: NORTHEAST MEDICAL GROUP 
PARTNERS HEALTHCARE: BRIGHAM AND WOMEN’S HOSPITAL 
PARTNERS HEALTHCARE: MASSACHUSETTS GENERAL HOSPITAL 
PARTNERS HEALTHCARE: FAULKNER HOSPITAL 
PARTNERS HEALTHCARE: COOLEY DICKINSON HOSPITAL 
PARTNERS HEALTHCARE: MARTHA’S VINEYARD HOSPITAL 
PARTNERS HEALTHCARE: MCLEAN HOSPITAL 
PARTNERS HEALTHCARE: NANTUCKET COTTAGE HOSPITAL 
PARTNERS HEALTHCARE: NEWTON-WELLESLEY HOSPITAL 
PARTNERS HEALTHCARE: NORTH SHORE MEDICAL CENTER 
PARTNERS HEALTHCARE: PARTNERS COMMUNITY PHYSICIANS  
PARTNERS HEALTHCARE: WENTWORTH-DOUGLASS HOSPITAL 
 
 
Study Title: INITIATING BUPRENORPHINE IN PATIENTS HOSPITALIZED WITH 
INTRAVENOUS DRUG-USE-RELATED ENDOCARDITIS 
 
Principal Investigator: Naiska Y. Cheung, PA-SII; Patrick O’Connor, MD, MPH, FACP 
 
Funding Source: Pending 
 
Consent to Participate in Research 
You are being invited to participate in a research study designed to investigate the 
efficacy of different treatment strategies for secondary prevention of intravenous drug 
use-related infective endocarditis. You have been asked to participate because you are 18 
years or older; have a DSM-V diagnosis of substance use disorder; and provided a urine 
sample positive for opioids. We expect to enroll 196 adults across all study sites. 
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In order to decide whether or not you wish to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision.  This 
consent for gives you detailed information about the research study, which a member of 
the research team will discuss with you.  Before you agree, a member of the research 
team must tell you about (i) the procedures and duration of the research; (ii) any 
reasonably foreseeable risks, discomforts, and benefits of the research; (iii) any 
potentially beneficial alternative procedures or treatments; and (iv) how confidentiality 
will be maintained.  Once you understand the study, you will be asked if you wish to 
participate. 
If you agree to participate, you must be given a signed copy of this document and a 
written summary of the research. 
Description of Procedures 
 Once enrolled in this study, you will be asked to fill out a form for us to better 
know you. 
 You will be randomly chosen to receive one of two treatment options offered.  
The two treatment options include sublingual buprenorphine combined with referral and 
referral alone. 
 If you are chosen to receive buprenorphine, your care team will independently 
evaluate your opioid withdrawal severity using the Clinical Opiate Withdrawal Scale 
(COWS) as a guide for opioid use disorder treatment initiation.  Buprenorphine treatment 
is clinically indicated for moderate-to-severe opioid withdrawal symptoms.  If 
buprenorphine treatment is not indicated during your hospitalization, we will provide you 
with a prescription for buprenorphine and detailed instructions on when and how to take 
the medication at home.  Referral to ongoing treatment will be provided to you, along 
with information pamphlets of facilities covered by your insurance. 
 If you are chosen to receive referral alone, your care team will provide you with a 
referral to an opioid use disorder treatment provider and information pamphlets for 
facilities covered by your insurance. 
 Regardless of the treatment course you are chose for, we highly encourage you to 
enroll in opioid use disorder treatment after you have been discharged.  You will return 
for follow-up with our research team in one (1) month and three (3) months after 
discharge.   
At each follow-up visit you will be asked to provide a urine sample for opioid 




Risks and Inconveniences 
 Sublingual buprenorphine adverse reactions include headache (29%), insomnia 
(21%), sweating (13%), nausea (14%), abdominal pain (12%), constipation (8%), and 
vomiting (8%).  This medication may impair your ability to drive or operate machinery.  
Less common complications include allergy/anaphylaxis, hypotension, arrhythmia, and 
respiratory depression.  This medication should not be taken with other depressants or 
sedatives such as benzodiazepines or alcohol due to risk of overdoese, coma or death.   
 
Benefits 
 Potential benefits from treatments include opioid use abstinence and treatment of 
withdrawal symptoms that include: yawning, lacrimation, rhinorrhea, nausea, emesis, 
diarrhea, hypertension, chills, piloerection, myalgias, abdominal pain, tremor, anxiety, 
agitation, delirium, and seizures. 
 
Economic Considerations 
 The cost of treatment involves several charges, including fees charged by your 
care team, the cost of buprenorphine (if applicable), and opioid use disorder treatment 
provider charges after discharge. 
 Your health insurance will partially or completely cover these costs.  If you do not 
have health insurance, your case manager will direct you to the appropriate resources for 
potential financial assistance. 
 
Treatment Alternatives/Alternatives 
 The most common treatment medical alternatives to buprenorphine maintenance 
therapy include methadone, naltrexone, and detoxification/non-medication treatment. 
 
Confidentiality 
 Research materials will be stored in locked cabinets and shredded before 
discarding.  Digital data will be stored and analyzed only on properly encrypted devices.  
All identifiable information will be deidentified prior to analysis to ensure confidentiality.  
When the results of the research are published or discussed in conferences, no 
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information will be included that would reveal your identity unless your specific consent 
for this activity is obtained. 
 Participating in this study is voluntary.  You are free to refuse your participation 
in this study.  Refusing to participate will involve no penalty or loss of benefits to which 
you would otherwise be entitled.  However, you will not be able to enroll in this research 
study and will not receive study procedures as a study participant if you do not allow the 
use of your information as part of this study. 
 You do agree to become a subject, you are free to stop and withdraw from this 
study at any time during its course.  To withdraw from the study, you can call a member 
of the research team at any time and tell them you no longer want to take part.  This will 
cancel any future appointments. 
 The researchers may withdraw you from participating in the research if necessary.  
Conditions under which a subject might be withdrawn from the research include, but are 
not limited to, when the subject is no longer a suitable candidate due to health, or the 
subject develops serious side effects or complictions to treatment. 
 Withdrawing from the study will involve no penalty or loss of benefits to which 
you are otherwise entitled.  It will not harm your relationship with your doctors or with 
the affiliated institute. 
 When you withdraw from the study, no new health information identifying you 
will be gathered after that date.  Information that has already been gathered may still be 
used until the end of the research study, as necessary to ensure the integrity of the study 
and/or study oversight. 
 
Questions 
 We have used some technical terms in this form.  Please feel free to ask about 
anything you do not understand and to consider this research and consent form 
carefully—as long as you feel is necessary—before you make a decision. 
I, ________________________________, have read (or someone has read to me) this 
form and have decided to participate in the project described above.  Its general purposes, 
the particulars of my involvement and possible hazards and inconveniences have been 
explaine to my satisfaction.  My signature indicates that I have received a copy of this 
consent form. 
________________________ ________________________ ____________ 




__________________________________    ________________ 
Signature of Principal Investigator      Date 




_________________________________    ______________ 
Signature of Person Obtaining Consent     Date 
 
 
You may contact Naiska Y. Cheung, PA-SII at (123) 456-7890 any time you have 
questions about the research or what to do if you are injured. 
If you have any questions about your privacy rights, please contact the Yale Privacy 
Officer at 203-432-5919.   
If you would like to talke with someone other than the researchers to discuss problems, 
concerns, and questions you may have concerning this research, or to discuss your rights 
as a research subject, you may contact the Yale Human Investigation Committee/Yale 
Human Research Protection Program (HRPP) at 203-785-4688.
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